At a glance
- Originator Eli Lilly and Company
- Class Antineoplastics; Stilbenes
- Mechanism of Action Selective estrogen receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Breast cancer; Endometriosis
Most Recent Events
- 28 Nov 2000 No-Development-Reported for Breast cancer in USA (Unknown route)
- 28 Nov 2000 No-Development-Reported for Endometriosis in USA (Unknown route)
- 08 Dec 1997 Preclinical development for Breast cancer in USA (Unknown route)